Pyc Therapeutics Ltd has released a press release.
Quarterly Activities and Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- Successful Completion of Key Translational Milestone
- Retina Target Engagement Confirmed in Large Eye
- Second Drug Program Progressing Towards Human Trials
- March 2021 Quarterly Report and Cashflow
- Lead Investigational Drug Demonstrates Key Improvement
Later from PYC Therapeutics
- PYC Increases Shareholding in Vision Pharma
- Preliminary Final Report
- Central Nervous System Drug Program Added to PYC Pipeline
- Successful Toxicology Studies Pave Way for Human Trials
- VP-001 IND Lodgement
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics